Clinical Trial Update: Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC [Phase 2]

View source ↗

Summary

Phase II randomized trial comparing patient-specific adaptive dosing versus continuous dosing of Abiraterone acetate or Enzalutamide for metastatic castration-r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Enzalutamide (enzalutamide)

Snippet

Sponsor: Leiden University Medical Center | Conditions: Prostatic Neoplasms, Castration-Resistant | Phase 2 | Status: RECRUITING